Spero Therapeutics, Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Spero Therapeutics, Inc. (SPRO) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $0 as of 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2024-03-13
- 2023-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $0.00.
- 2022-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $201.00K.
- 2021-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $468.00K.
- 2020-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $736.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-13 |
| 2022-12-31 | $201.00K 10-K · filed 2024-03-13 |
| 2021-12-31 | $468.00K 10-K · filed 2023-03-30 |
| 2020-12-31 | $736.00K 10-K · filed 2022-03-31 |
| 2020-09-30 | $803.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $870.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $937.00K 10-Q · filed 2020-05-08 |
| 2019-12-31 | $1.00M 10-K · filed 2021-03-11 |
| 2019-09-30 | $1.27M 10-Q · filed 2019-11-04 |
| 2019-06-30 | $1.35M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.43M 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |